Transgene (FRA:TGNA) Short Interest


FRA:TGNA Transgene SA FRA:TGNA
47 GF Score
Price €0.70
GF Value €0.51
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:TGNA vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Transgene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Short Interest distribution charts can be found below:

* The bar in red indicates where Transgene's Short Interest falls into.


FRA:TGNA
47GF Score
Transgene SA FRA:TGNA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (FRA:TGNA) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.70 is trading 37.8% above its estimated GF Value™ of €0.51. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for FRA:TGNA:

  • Short Interest:
  • GF Value™: €0.51 vs. price of €0.70 (37.8% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the FRA:TGNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Other Exchanges TRGNF:USA0OCQ:UKTNG:France
Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
47GF Score

Get the complete analysis for FRA:TGNA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.70
Price
€0.51
GF Value